List of Excipients in Branded Drug TYRUKO

TYRUKO Excipient Strategy and Commercial Opportunities in Natalizumab Biosimilars

Last updated: August 9, 2026

TYRUKO (natalizumab-sztn) is a 300 mg/15 mL intravenous biosimilar to TYSABRI. Its excipient strategy uses a conventional low-pH phosphate-buffered formulation with sodium chloride, polysorbate 80, and water for injection. The formulation supports a preservative-free, single-dose vial administered every four weeks. The main commercial opportunity is biosimilar price competition in multiple sclerosis and Crohn's disease, not differentiated excipient protection.

What excipients are used in TYRUKO?

TYRUKO contains a limited excipient package designed to maintain natalizumab solubility, reduce aggregation, and support intravenous administration.

Formulation component	Function
Natalizumab-sztn	Monoclonal antibody active ingredient
Sodium chloride	Isotonicity adjustment
Sodium phosphate monobasic monohydrate	Buffer component
Sodium phosphate dibasic heptahydrate	Buffer component
Polysorbate 80	Surfactant that limits interfacial adsorption and aggregation
Water for injection	Vehicle

TYRUKO is supplied as a 20 mg/mL concentrate in a 15 mL single-dose vial. The 300 mg dose is diluted in 100 mL of 0.9% sodium chloride injection and administered by intravenous infusion over approximately one hour every four weeks. The product does not use a preservative, which is standard for a sterile biologic supplied in a single-use vial. [1]

Why is polysorbate 80 important in TYRUKO?

Polysorbate 80 reduces protein adsorption to vial, syringe, tubing, and infusion-bag surfaces. It also helps control agitation-induced particle formation during manufacturing, shipping, dilution, and administration.

For natalizumab, polysorbate management creates a technical control point. The excipient can undergo oxidation or hydrolysis, generating degradation products that may affect antibody stability or increase subvisible particles. Commercial manufacturers therefore need control over:

• Polysorbate identity and lot variability
• Peroxide levels
• Oxidative stress during storage
• Contact with metal ions and oxygen
• Container-closure interaction
• Freeze-thaw and agitation exposure

The label does not identify a novel surfactant system or an excipient-based clinical differentiator for TYRUKO. The public formulation is aligned with the established TYSABRI dosage form. [1, 2]

What is the role of the phosphate buffer?

The sodium phosphate system controls formulation pH and helps preserve the antibody's conformation during refrigerated storage. Buffer concentration and pH affect aggregation, viscosity, deamidation, oxidation, and adsorption.

The commercial value of this excipient system is primarily manufacturing reliability. A biosimilar sponsor must demonstrate that the product remains highly similar to the reference product across physicochemical, functional, and stability tests. Excipient changes can influence the comparability package even when the active antibody sequence is unchanged.

How does TYRUKO compare with TYSABRI excipients?

TYRUKO is intended to match TYSABRI's clinically relevant product characteristics, including route, strength, dose, and administration schedule. Both products use a phosphate-buffered formulation containing sodium chloride and polysorbate 80. [1, 2]

Attribute	TYRUKO	TYSABRI
Active ingredient	Natalizumab-sztn	Natalizumab
Strength	20 mg/mL	20 mg/mL
Vial volume	15 mL	15 mL
Dose	300 mg	300 mg
Route	Intravenous infusion	Intravenous infusion
Standard interval	Every four weeks	Every four weeks
Preservative	None	None
Surfactant	Polysorbate 80	Polysorbate 80
Buffer	Sodium phosphate system	Sodium phosphate system
Diluent	0.9% sodium chloride	0.9% sodium chloride

The comparison is commercially relevant because a familiar excipient profile reduces pharmacy and infusion-center switching friction. TYRUKO can use existing handling procedures for dilution, infusion, storage, and preparation, subject to product-specific labeling.

What commercial opportunities does TYRUKO's excipient strategy create?

The formulation creates opportunities in procurement, manufacturing, contract development, and biosimilar portfolio expansion.

Lower-cost excipient procurement

The excipients are established pharmaceutical-grade materials available from multiple suppliers. They do not create the same supply constraint associated with specialized lipids, novel stabilizers, or proprietary delivery systems.

Procurement priorities include:

• Pharmaceutical-grade polysorbate 80 with controlled peroxide content
• Consistent phosphate-buffer raw materials
• Low-bioburden and low-endotoxin water systems
• Validated single-use and stainless-steel process-contact materials
• Reliable vial, stopper, and seal suppliers

The largest formulation-related supply risk is likely to be polysorbate variability rather than phosphate or sodium chloride availability.

Contract manufacturing and fill-finish

TYRUKO's presentation is compatible with existing monoclonal-antibody fill-finish infrastructure. Commercial service providers can compete on:

• Aseptic filling of 15 mL single-dose vials
• Low-shear handling
• Particle and visible-inspection performance
• Cold-chain packaging
• Dilution and in-use stability studies
• Secondary packaging for restricted distribution

The formulation does not eliminate the need for specialized biologics manufacturing. Natalizumab requires mammalian-cell production, purification, viral-clearance operations, aggregation control, and validated aseptic filling.

Formulation analytics

Testing services have commercial value because polysorbate-containing biologics require more than basic release assays. Relevant methods include:

• Size-exclusion chromatography for soluble aggregates
• Subvisible-particle testing
• Host-cell protein and residual-DNA assays
• Polysorbate concentration and degradation testing
• Oxidation and chemical-degradation profiling
• Charge-variant analysis
• Potency and cell-adhesion functional assays

These analytical controls support both release testing and post-approval process monitoring.

Future presentation development

The current TYRUKO presentation is intravenous. Potential future opportunities could include:

• Ready-to-use infusion formats
• Larger-volume or pharmacy-optimized containers
• Closed-system transfer devices
• Reduced-waste dilution systems
• Alternative delivery formats if supported by clinical and regulatory data

A prefilled syringe or subcutaneous presentation would require a separate development and regulatory strategy. It could also create new challenges involving viscosity, device compatibility, injection force, container closure, and surfactant stability. The current FDA approval does not authorize these formats. [3]

What FDA regulatory status affects TYRUKO's commercial prospects?

The FDA approved TYRUKO on August 24, 2023, under the abbreviated licensure pathway for biosimilars under section 351(k) of the Public Health Service Act. It is approved for adults with relapsing forms of multiple sclerosis and for adults with moderately to severely active Crohn's disease when other therapies have not produced an adequate response. [3]

TYRUKO is subject to the natalizumab risk-management framework because of the risk of progressive multifocal leukoencephalopathy, or PML. Prescribing and dispensing occur through the TYRUKO TOUCH Prescribing Program. This restricted-distribution structure affects market access, pharmacy operations, patient enrollment, and switching logistics. [1]

The FDA approval does not establish TYRUKO as interchangeable with TYSABRI. Biosimilar status and interchangeability are separate regulatory designations. Automatic pharmacy substitution generally depends on an FDA interchangeability determination and applicable state law.

Does TYRUKO have Orange Book patents or Paragraph IV challenges?

TYRUKO is a biologic and is not evaluated through the conventional small-molecule ANDA and Orange Book Paragraph IV process. Its relevant regulatory reference is the Purple Book, which identifies licensed biological products and biosimilar relationships. [4]

Legal or regulatory issue	TYRUKO position
ANDA pathway	Not applicable
Orange Book listing	Not the primary biologic reference
Paragraph IV certification	Not applicable to the 351(k) approval pathway
Biosimilar pathway	Section 351(k)
Reference product	TYSABRI
Interchangeability	Not established by the original biosimilar approval
Risk-management program	TYRUKO TOUCH

The commercial launch timetable can still be affected by patent litigation, settlement agreements, licensing arrangements, and patent-law obligations under the Biologics Price Competition and Innovation Act. Those issues do not appear as a conventional Orange Book patent table.

What patents protect TYRUKO and natalizumab formulations?

The public FDA labeling identifies the product, indication, dosage, route, and excipients but does not establish a complete patent estate for natalizumab or TYRUKO. Formulation protection could theoretically involve:

• Specific phosphate-buffer concentrations
• Polysorbate concentration ranges
• pH windows
• Low-aggregation formulations
• Container-closure systems
• Storage conditions
• Diluted infusion stability
• Manufacturing and purification processes
• Antibody sequence or binding claims
• Method-of-use claims for multiple sclerosis or Crohn's disease

These categories should not be treated as confirmed TYRUKO patent claims. The public product label does not demonstrate that any particular excipient ratio is proprietary or that TYRUKO relies on a formulation patent.

For biosimilar competitors, the main IP barriers are likely to involve reference-product patent strategy, manufacturing know-how, regulatory exclusivity, and launch timing. An excipient package based on widely used pharmaceutical ingredients is unlikely, by itself, to create a durable market barrier.

When does TYRUKO lose exclusivity?

TYRUKO's commercial protection is different from small-molecule exclusivity.

TYSABRI received FDA approval in 2004. The statutory reference-product exclusivity period for a biologic is generally 12 years from first licensure, but that period does not operate as a new exclusivity term for TYRUKO. TYRUKO entered through the biosimilar pathway after the reference product's core regulatory exclusivity period had expired. [3, 5]

TYRUKO's practical exclusivity depends on:

• Patent and settlement outcomes
• Biosimilar competition
• FDA approval of additional natalizumab products
• Payer formulary placement
• TOUCH-program access
• Manufacturing capacity
• Contracting with infusion providers
• Potential interchangeability designation

No conventional generic cliff applies. Competition can develop through multiple biosimilar approvals and negotiated market entry.

Which companies are challenging the natalizumab market?

The primary commercial comparison is between Biogen's TYSABRI and Sandoz's TYRUKO. Other companies may pursue natalizumab biosimilars, but approval status, launch timing, and commercial availability must be assessed product by product through FDA and international regulatory records.

Company	Product	Market role
Biogen	TYSABRI	Reference natalizumab product
Sandoz	TYRUKO	FDA-approved natalizumab biosimilar
Other developers	Natalizumab candidates or regional products	Competitive pipeline and regional risk

The competitive threat is strongest in high-volume multiple-sclerosis treatment centers, where infusion infrastructure already exists. Crohn's disease presents a smaller but relevant opportunity because natalizumab is used selectively after inadequate response to other therapies.

How strong is the TYRUKO formulation strategy?

The formulation strategy is operationally strong but weak as a standalone differentiation platform.

Its advantages are:

• Familiar excipients
• Established intravenous dosing
• Preservative-free single-dose presentation
• Compatibility with standard saline dilution
• Limited raw-material complexity
• Reduced switching burden for infusion centers

Its limitations are:

• No visible excipient novelty
• Dependence on cold-chain biologics logistics
• Polysorbate degradation risk
• No current subcutaneous or ready-to-use differentiation
• Restricted-distribution requirements
• Limited ability to create product-level exclusivity from common excipients

The formulation supports biosimilar comparability and cost-efficient manufacturing. It does not, based on the public label, provide a clear patent moat.

What generic and biosimilar entry risks exist for TYRUKO?

TYRUKO faces biosimilar erosion rather than traditional generic substitution. The main scenarios are:

1. A second natalizumab biosimilar competes on net price.
2. A competitor obtains interchangeability and gains pharmacy-substitution advantages.
3. Payers place multiple natalizumab products on preferred tiers.
4. Infusion providers switch based on acquisition cost and reimbursement spread.
5. A new delivery format reduces administration burden.
6. Manufacturing disruptions affect supply reliability.

The highest-value commercial differentiators are likely to be net price, supply continuity, payer access, patient-support services, and interchangeability status. Excipient differences alone are unlikely to determine prescribing decisions.

What revenue exposure does TYRUKO create?

TYRUKO targets a large established natalizumab franchise rather than a new treatment category. TYSABRI has generated multibillion-dollar annual revenue for Biogen across multiple years, making natalizumab one of the most commercially significant mature biologic opportunities in neurology. [6]

Annual dosing is approximately 13 infusions per patient when administered every four weeks. At 300 mg per dose, one continuously treated patient represents approximately 3.9 grams of natalizumab annually before dose interruptions or extended-interval regimens.

Revenue opportunity depends on:

• Number of treated patients
• Share captured from TYSABRI
• Biosimilar discount
• Rebates and payer contracts
• Infusion-center economics
• Persistence and switching rates
• Geographic launch sequence

The excipient strategy helps protect gross margin by relying on standard materials and existing biologics infrastructure. It does not determine the size of the addressable market.

Key Takeaways

• TYRUKO uses sodium chloride, phosphate buffer, polysorbate 80, and water for injection.
• Polysorbate 80 is the principal formulation-risk excipient because of oxidation, hydrolysis, and particle-generation concerns.
• The 300 mg/15 mL single-dose vial is preservative-free and diluted in 0.9% sodium chloride before intravenous infusion.
• The formulation is commercially efficient but does not show clear excipient-based differentiation.
• TYRUKO was FDA-approved in 2023 as a natalizumab biosimilar for multiple sclerosis and Crohn's disease.
• TYRUKO operates under the TYRUKO TOUCH restricted-distribution program.
• Orange Book Paragraph IV analysis does not apply in the conventional small-molecule sense; biologic competition is assessed through the 351(k) pathway, Purple Book records, patent litigation, and settlements.
• The strongest commercial opportunities are lower-cost supply, fill-finish services, analytical testing, payer contracting, and future delivery-format development.
• The largest risks are additional biosimilar entry, interchangeability competition, payer pressure, manufacturing complexity, and natalizumab risk-management requirements.

FAQs

Can TYRUKO be mixed with infusion solutions other than normal saline?

The FDA label specifies dilution in 0.9% sodium chloride injection. Alternative diluents should not be treated as approved TYRUKO administration options. [1]

Does TYRUKO contain human serum albumin?

The FDA inactive-ingredient listing for TYRUKO does not identify human serum albumin. Its stabilizer system uses phosphate salts and polysorbate 80. [1]

Can excipient differences prevent biosimilar approval?

Yes. A formulation difference can affect analytical similarity, stability, immunogenicity, or clinical performance. FDA approval depends on the totality of evidence, not on identical excipient composition alone. [5]

Is TYRUKO suitable for at-home self-administration?

The approved product is administered by intravenous infusion under the product's prescribing and risk-management requirements. The current label does not authorize routine self-administration. [1]

Could a future natalizumab product use a different surfactant?

A future product could use another surfactant or delivery system if it establishes acceptable stability, comparability, safety, and efficacy. Such a change would represent a separate product-development and regulatory strategy.

References

1. U.S. Food and Drug Administration. (2023). TYRUKO (natalizumab-sztn) injection, prescribing information.
2. U.S. Food and Drug Administration. (2023). TYSABRI (natalizumab) injection, prescribing information.
3. U.S. Food and Drug Administration. (2023, August 24). FDA approves first biosimilar to Tysabri to treat multiple sclerosis and Crohn’s disease.
4. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products.
5. U.S. Food and Drug Administration. (2015). Biosimilars: Questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009.
6. Biogen Inc. (2024). 2023 annual report.